CMV

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
BrincidofovirPhase 3Small Molecule1 trial
Active Trials
NCT01769170Completed452Est. Jan 2016
M&
Merck & Co.RAHWAY, NJ
1 program
Real time PCRN/A1 trial
Active Trials
NCT04280380Unknown400Est. Dec 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Jazz PharmaceuticalsBrincidofovir
Merck & Co.Real time PCR

Clinical Trials (2)

Total enrollment: 852 patients across 2 trials

A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients

Start: Aug 2013Est. completion: Jan 2016452 patients
Phase 3Completed

Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy

Start: Mar 2020Est. completion: Dec 2022400 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space